SCHEMBL16742928

SCHEMBL16742928

Fc1[c]ccc(N2CCOCC2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 1/20 0.42
▸ PIM1 P11309 1/20 0.42
▸ HTT P42858 1/20 0.41
▸ MAPT P10636 3/20 0.41
▸ SMPD3 Q9NY59 1/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ CYP1A2 P05177 2/20 0.40
▸ PIK3CD O00329 1/20 0.40
▸ PIK3CA P42336 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ CLK4 Q9HAZ1 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ PRKDC P78527 1/20 0.39
▸ SHMT2 P34897 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1819991 0.79 KMT2A (0.46) GAAHTTMAPTSMPD3KMT2A
SCHEMBL10519207 0.79 CYP1A2 (0.45) GAAPIM1HTTMAPTSMPD3
SCHEMBL2744690 0.73 KDM4E (0.45) GAAHTTMAPTSMPD3KMT2A
SCHEMBL2371248 0.71 GAA (0.51) GAAPIM1HTTMAPTSMPD3
SCHEMBL30818693 0.71 GAA (0.51) GAAPIM1HTTMAPTSMPD3
SCHEMBL6843345 0.71 GAA (0.59) GAAHTTMAPTSMPD3KMT2A
SCHEMBL2744076 0.69 KDM4E (0.41) GAAHTTMAPTKMT2AHSD17B10
SCHEMBL24195931 0.69 SMPD3 (0.47) GAAPIM1HTTMAPTSMPD3
SCHEMBL25333250 0.69 GAA (0.45) GAAPIM1HTTMAPTSMPD3
SCHEMBL16908180 0.69 SMPD3 (0.50) GAAPIM1HTTMAPTSMPD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3071578-B1 TRICYCLIC PIPERIDINE COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2018-01-10 — — EP disclosed
US-9765092-B2 Tricyclic piperidine compounds ACTELION PHARMACEUTICALS LTD (CH) 2017-09-19 — — US disclosed
EP-3071578-A1 TRICYCLIC PIPERIDINE COMPOUNDS Actelion Pharmaceuticals Ltd (CH) 2016-09-28 — — EP disclosed
US-20160272655-A1 TRICYCLIC PIPERIDINE COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2016-09-22 — — US disclosed
WO-2015075023-A1 TRICYCLIC PIPERIDINE COMPOUNDS ACTELION PHARMACEUTICALS LTD (CH) 2015-05-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160272655-A1 TRICYCLIC PIPERIDINE COMPOUNDS TPH1, HTR1B, HTR1A GAA 2588/4885PIM1 4597/4885HTT 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback